Progression in Therapy of Erlotinib for Patients with Non-small Cell Lung Cancerr
Progression in Therapy of Erlotinib for Patients with Non-small Cell Lung Cancerr
About this item
Full title
Author / Creator
MENG, Fanlu and Li, MA
Publisher
Tianjin: Chinese Anti-Cancer Association Chinese Antituberculosis Association
Journal title
Language
Chinese
Formats
Publication information
Publisher
Tianjin: Chinese Anti-Cancer Association Chinese Antituberculosis Association
Subjects
More information
Scope and Contents
Contents
在世界范围内肺癌的发病率呈上升趋势，目前以手术和放化疗为主的综合疗法是治疗的主要手段。由于化疗可对造血、神经、消化等多系统造成损害从而部分影响了疗效，不良反应较轻的靶向治疗成为近年来内科治疗的研究热点。应该何时选用靶向治疗；与化疗同时进行能否使患者受益；如果不同时应用，它们的先后顺序如何；靶向治疗对于脑转移癌的治疗是否有效等诸多问题都备受关注，众多大规模临床试验正在进行中，本文将靶向药物——厄洛替尼在治疗非小细胞肺癌（nonsmall cell lung cancer, NSCLC）方面的最新临床研究结果加以总结。 1 厄洛替尼单药的二线及三线治疗 厄洛替尼是表皮生长因子受体酪氨酸激酶抑制剂（epidermal growth factor receptor tyrosine kinase i...
Alternative Titles
Full title
Progression in Therapy of Erlotinib for Patients with Non-small Cell Lung Cancerr
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2127378419
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2127378419
Other Identifiers
ISSN
1009-3419
E-ISSN
1999-6187
